In the two tumor models (B16.F10 and J558) tested, intra-tumoral delivery of high dose AAV-IL-27 showed potent anti-tumor activity in mice bearing plasmacytoma J558 tumors and modest anti-tumor activity in mice bearing B16.F10 tumors. Here, IL27 is linked to plasmacytoma.